Psychoneuroendocrinology
Volume 34, Issue 7 , Pages 989-995 , August 2009

Sexual dysfunction and hormonal changes in first episode psychosis patients on olanzapine or risperidone

Received 11 July 2008 ,Revised 23 January 2009 ,Accepted 28 January 2009.

References 

  1. Dickson RA, Glazer WM. Hyperprolactinemia and male sexual dysfunction. J. Clin. Psychiatry. 1999;60(2):125
  2. Dunn KM, Jordan K, Croft PR. Systematic review of sexual problems: epidemiology and methodology. J. Sex Marital Ther. 2002;28:399–422
  3. Fleischhacker WW. New drugs for the treatment of schizophrenic patients (Review) (102 Refs). Acta Psychiatr. Scand. Suppl. 1995;388:24–30
  4. Fortier P, Mottard JP, Trudel G, Even S. Study of sexuality-related characteristics in young adults with schizophrenia treated with novel neuroleptics and in a comparison group of young adults. Schizophrenia Bull. 2003;29(3):559–572
  5. Gitlin MJ. Psychotropic medications and their effect on sexual functioning: diagnosis, biology and treatment approaches. J. Clin. Psychiatry. 1994;55:406–413
  6. Halbreich U, Kahn LS. Hormonal aspects of schizophrenias: an overview. Psychoneuroendocrinology. 2003;28(Suppl 2):1–16
  7. Hansen TE, Casey DE, Hoffman WF. Neuroleptic intolerance. Schizophrenia Bull. 1997;23(4):567–582
  8. Ishigooka J, Murasaki M, Miura S. Olanzapine optimal dose: results of an open-label multicenter study in schizophrenic patients. Olanzapine Late-Phase II Study Group. Psychiatry Clin. Neurosci. 2000;54(4):467–478
  9. Knegtering H, Lambers PA, Prakken G, Brink ten C. Serum prolactin levels and sexual dysfunction in antipsychotic medication, such as risperidone: a review. Acta Neuropsychiatrica. 2000;1:19–26
  10. Knegtering H, Moolen van der AEGM, Castelein S, Kluiter H, Bosch van den RJ. What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning?. Psychoneuroendocrinology. 2003;28(Suppl. 2):109–123
  11. Knegtering H, van den Bosch R, Castelein S, Bruggeman R, Sytema S, van Os J. Are sexual side effects of prolactin-raising anti-psychotics reducible to serum prolactin?. Psychoneuroendocrinology. 2008;33:711–717
  12. Lavalaye J, Linszen DH, Booij J, Reneman L, Gersons BP, van Royen EA. Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia. Psychiatry Res. 1999;92(1):33–44
  13. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Res. 1999;35(1):51–68
  14. Liu CY, Chiu NY, Wu CK, Yuan LM, Hsiao MC, Liao O. Optimal dose of risperidone and olanzapine for patients with schizophrenia in Taiwan. Int. Clin. Psychopharmacol. 2003;18(1):49–51
  15. Petty RG. Prolactin and antipsychotic medications: mechanism of action. Schizophrenia Res. 1999;35:S67–S73
  16. Selmanoff M. The lateral and median eminence: distribution of dopamine, norepinephrine and luteinizing hormone-releasing hormone and the effect of prolactin on catecholamine turnover. Endocrinology. 1981;108:1716–1722
  17. Smith S, Wheeler MJ, Murray R, O’Keane V. The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic–pituitary–gonadal axis. J. Clin. Psychopharmacol. 2002;22:109–114
  18. Vroege, J.A., 1995. Questionnaire for screening sexual dysfunction (QSD), 5th version. Department of Psychiatry, Leiden University Medical Center and Dutch Institute for Social Sexuology Research (NISSO), The Netherlands.
  19. Williams HJ. Textbook of Endocrinology. 8th ed.. Philadelphia: Wilson and Foster; 1992;
  20. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry. 2003;64(6):663–667

PII: S0306-4530(09)00031-6

doi: 10.1016/j.psyneuen.2009.01.013

Psychoneuroendocrinology
Volume 34, Issue 7 , Pages 989-995 , August 2009

Article Tools